CPC G01N 33/57438 (2013.01) [C12Q 1/6886 (2013.01); G01N 33/5302 (2013.01); C12Q 2600/158 (2013.01)] | 16 Claims |
1. A method of treating pancreatic cancer in a subject comprising the steps of:
(a) determining in a sample of a subject suspected to suffer from pancreas cancer the amount of at least three polypeptide biomarkers selected from TMM54, MK12, MELPH, UN93B, COXAM, RASF1, AKTIP, CASPA, CDN2B, CLD7, DCOR, EWS, FAK1, GPX4, HMGB2, IGF1A, IRS2, K2C8, LYAM1, MAD4, MMP1, MMP7, S10A6, SORL, and TNR6, wherein the sample is a blood, plasma, serum, or urine sample, wherein the amount is determined with an immunoassay, wherein the immunoassay comprises:
(i) contacting the sample with an antibody microarray comprising antibodies that recognize the at least three polypeptide biomarkers, and
(ii) measuring the amounts of bound biomarkers and thereby determining the amounts of the biomarkers present in the sample;
(b) comparing the amount of the at least three biomarkers with a reference to determine if the subject suffers from pancreas cancer, wherein a decrease in the amount of AKTIP, CASPA, CDN2B, CLD7, IRS2, LYAM1, SORL, COXAM, EWS, FAK1, IGF1A, K2C8, MAD4, MELPH, MK12, MMP1, MMP7, S10A6, TMM54, TNR6, and UN93B compared to the reference is indicative of pancreatic cancer, and/or an increase in the amount of DCOR, GPX4, HMGB2, or RASF1 as compared to the reference is indicative of pancreatic cancer; and
(c) treating the subject with a pancreas cancer therapy if the subject is determined to suffer from pancreas cancer.
|